ASSEMBLY BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.07 USD | -0.07% |
|
-0.59% | +53.13% |
Presenter SpeechLauren Glaser (Executives)Okay. So we just wanted to welcome you all to Assemb...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Companyâs pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.
Sector
Pharmaceuticals
Calendar
28/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
15.07
USD
Average target price
36
USD
Spread / Average Target
+138.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +53.13% | 83.14M | |
| +16.34% | 79.03B | |
| +8.38% | 8.78B | |
| -16.33% | 4.83B | |
| +51.22% | 4.65B | |
| +2.18% | 3.89B | |
| +20.51% | 2.34B | |
| -26.79% | 2.18B | |
| +15.12% | 2.11B | |
| -36.56% | 2B |
- Stock Market
- Equities
- ASMB Stock
- News Assembly Biosciences, Inc.
- Transcript : Assembly Biosciences, Inc. - Special Call
